Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Westerink

Showing results (41-50 of 118) with videos related to

Pageof 12
Sort By:
BMC Public Health|April 6, 2022
Modifiable risk factors in adults with and without prior cardiovascular disease: findings from the Indonesian National Basic Health ResearchDian Sidik Arsyad, Jan Westerink, Maarten J Cramer, et al.
European Journal of Preventive Cardiology|July 24, 2018
Combined use of polypill components in patients with type 2 diabetes mellitusVivi E Janssen, Frank L Visseren, Anthonius de Boer, et al.
Atherosclerosis|July 6, 2010
Vascular and metabolic effects of 12 days intensive walking to Santiago de CompostelaRemy H H Bemelmans, Blai Coll, Daniel R Faber, et al.
Orphanet Journal of Rare Diseases|July 8, 2022
The long-term effect of mTOR inhibition on lipid and glucose metabolism in tuberous sclerosis complex: data from the Dutch TSC registryFemke V M Mulder, Evelien F H I Peeters, Jan Westerink, et al.
Lipids|January 22, 2014
An oral mixed fat load is followed by a modest anti-inflammatory adipocytokine response in overweight patients with metabolic syndromeJan Westerink, Gideon R Hajer, Mariëtte E G Kranendonk, et al.
BMC Emergency Medicine|December 21, 2022
Shorter laboratory turnaround time is associated with shorter emergency department length of stay: a retrospective cohort studyBram E L Vrijsen, Saskia Haitjema, Jan Westerink, et al.
European Journal of Endocrinology|October 12, 2021
Insulin resistance and risk of vascular events, interventions and mortality in type 1 diabetesMarga A G Helmink, Marieke de Vries, Frank L J Visseren, et al.
Hypertension (Dallas, Tex. : 1979)|December 21, 2020
Applicability of Blood Pressure-Lowering Drug Trials to Real-World Patients With Cardiovascular DiseaseNadia E Bonekamp, Wilko Spiering, Hendrik M Nathoe, et al.
Journal of the American College of Cardiology|August 17, 2013
Low high-density lipoprotein cholesterol is not a risk factor for recurrent vascular events in patients with vascular disease on intensive lipid-lowering medicationAnton P van de Woestijne, Yolanda van der Graaf, An-Ho Liem, et al.
Rheumatology (Oxford, England)|May 27, 2025
DISH as a marker for incident diabetes mellitus in cardiovascular disease patientsNetanja I Harlianto, Wouter Foppen, Firdaus A A Mohamed Hoesein, et al.
Pageof 12

Showing results (41-50 of 118) with videos related to

Sort By:
Pageof 12
BMC Public Health|April 6, 2022
Modifiable risk factors in adults with and without prior cardiovascular disease: findings from the Indonesian National Basic Health ResearchDian Sidik Arsyad, Jan Westerink, Maarten J Cramer, et al.
European Journal of Preventive Cardiology|July 24, 2018
Combined use of polypill components in patients with type 2 diabetes mellitusVivi E Janssen, Frank L Visseren, Anthonius de Boer, et al.
Atherosclerosis|July 6, 2010
Vascular and metabolic effects of 12 days intensive walking to Santiago de CompostelaRemy H H Bemelmans, Blai Coll, Daniel R Faber, et al.
Orphanet Journal of Rare Diseases|July 8, 2022
The long-term effect of mTOR inhibition on lipid and glucose metabolism in tuberous sclerosis complex: data from the Dutch TSC registryFemke V M Mulder, Evelien F H I Peeters, Jan Westerink, et al.
Lipids|January 22, 2014
An oral mixed fat load is followed by a modest anti-inflammatory adipocytokine response in overweight patients with metabolic syndromeJan Westerink, Gideon R Hajer, Mariëtte E G Kranendonk, et al.
BMC Emergency Medicine|December 21, 2022
Shorter laboratory turnaround time is associated with shorter emergency department length of stay: a retrospective cohort studyBram E L Vrijsen, Saskia Haitjema, Jan Westerink, et al.
European Journal of Endocrinology|October 12, 2021
Insulin resistance and risk of vascular events, interventions and mortality in type 1 diabetesMarga A G Helmink, Marieke de Vries, Frank L J Visseren, et al.
Hypertension (Dallas, Tex. : 1979)|December 21, 2020
Applicability of Blood Pressure-Lowering Drug Trials to Real-World Patients With Cardiovascular DiseaseNadia E Bonekamp, Wilko Spiering, Hendrik M Nathoe, et al.
Journal of the American College of Cardiology|August 17, 2013
Low high-density lipoprotein cholesterol is not a risk factor for recurrent vascular events in patients with vascular disease on intensive lipid-lowering medicationAnton P van de Woestijne, Yolanda van der Graaf, An-Ho Liem, et al.
Rheumatology (Oxford, England)|May 27, 2025
DISH as a marker for incident diabetes mellitus in cardiovascular disease patientsNetanja I Harlianto, Wouter Foppen, Firdaus A A Mohamed Hoesein, et al.
Pageof 12